Related Experiment Videos
Vigabatrin in partial seizures in children
R C Nabbout1, C Chiron, J Mumford
1Department of Pediatric Neurology, Hôpital Saint Vincent de Paul, Paris, France.
Journal of Child Neurology
|April 1, 1997
Summary
Vigabatrin effectively reduced partial seizures in 70% of pediatric patients, with 30% achieving seizure freedom. However, efficacy varied by etiology, and early treatment was linked to better outcomes but higher relapse rates.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Partial seizures affect a significant pediatric population.
- Vigabatrin is an antiepileptic drug with established efficacy.
- Understanding treatment response in diverse pediatric populations is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of vigabatrin in pediatric patients with partial seizures.
- To identify factors influencing treatment response and relapse.
Main Methods:
- Prospective study of 175 pediatric patients (1 week to 19 years) with partial seizures.
- Treatment with vigabatrin, with seizure frequency and adverse events monitored.
- Analysis of response rates based on etiology, seizure focus topography, and age.
Main Results:
- 70% of patients achieved >50% seizure frequency reduction; 30% became seizure-free.
- Tuberous sclerosis showed the highest response rate (85%), while tumors had the lowest (45%).
- Early treatment and infant age correlated with better initial response but increased relapse risk.
Conclusions:
- Vigabatrin is effective for pediatric partial seizures, with response varying by underlying etiology and seizure focus.
- Early intervention and age are critical factors influencing treatment outcomes and relapse.
- Careful monitoring is needed, especially in infants and patients with specific etiologies like tuberous sclerosis.